|Bid||183.05 x 800|
|Ask||183.50 x 1100|
|Day's range||181.10 - 192.18|
|52-week range||74.45 - 236.17|
|PE ratio (TTM)||N/A|
|Earnings date||31 Jul 2018 - 6 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||215.29|
BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.
bluebird bio, Inc. announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent β-thalassemia and severe sickle cell disease will be highlighted in oral presentations at the 23rd Congress of the European Hematology Association .
CAMBRIDGE, Mass.--(BUSINESSWIRE)-- - Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β 0 /β ...
bluebird bio, Inc. announced that updated interim data from CRB-401, its Phase 1 study of bb2121, an anti-BCMA CAR T cell therapy being developed by the company and Celgene, will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
Both clinical-stage biotechs have cutting-edge cancer therapies in their pipelines. But which stock wins in a head-to-head matchup?
To access the live webcasts of bluebird bio’s presentations, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcasts will be available on the bluebird bio website for 90 days following the conferences. With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.31. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...
bluebird bio, Inc. today reported financial results and business highlights for the first quarter ended March 31, 2018.
New treatments could be coming from Celgene and bluebird bio that reshape how we treat this life-threatening gene disorder.
Researchers successfully used an experimental gene therapy developed by biotech company Bluebird Bio Inc. to reduce the number of blood transfusions needed in people with beta-thalassemia, an inherited ...
bluebird bio, Inc. (Nasdaq: BLUE) today announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT). Both studies, Northstar (HGB-204), which recently was completed, and HGB-205, which is ongoing, are evaluating the safety and efficacy of one-time treatment with LentiGlobin gene therapy and the interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions. Interim results also showed that all but one patient with a non-β0/β0 genotype (12 of 13 patients) stopped receiving regular red blood cell (RBC) transfusions, with a median time since last transfusion of 27 months.
bluebird bio, Inc. (BLUE) today announced interim data published in the New England Journal of Medicine (NEJM) from two separate two-year clinical studies investigating the potential for LentiGlobin™ gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia (TDT). Both studies, Northstar (HGB-204), which recently was completed, and HGB-205, which is ongoing, are evaluating the safety and efficacy of one-time treatment with LentiGlobin gene therapy and the interim results showed that a majority of the 22 patients in the two Phase 1/2 studies followed for two years or longer remained free from transfusions. Interim results also showed that all but one patient with a non-β0/β0 genotype (12 of 13 patients) stopped receiving regular red blood cell (RBC) transfusions, with a median time since last transfusion of 27 months.
bluebird bio, Inc. today announced that members of the management team will present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day on Tuesday, April 17, at 11:25 a.m.
Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
bluebird bio, Inc. and Celgene Corporation today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen chimeric antigen receptor T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.
The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.
Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology. In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings.